Diplomat Now Dispensing VOSEVI™ to Treat Chronic Hepatitis C Virus

FLINT, Mich., July 26, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) is now dispensing newly approved VOSEVI™ (sofosbuvir/velpatasvir/voxilaprevir) to treat hepatitis C virus infection.

VOSEVI is used to treat all genotypes of chronic hepatitis C virus infection. It is indicated for adults without cirrhosis (liver disease) or with compensated cirrhosis who have previously been treated with a regimen containing an NS5A inhibitor such as EPCLUSA^® (sofosbuvir/velpatasvir); HARVONI^® (ledipasvir/sofosbuvir); VIEKIRA PAK^™ or VIEKIRA XR^™ (dasabuvir/ombitasvir/paritaprevir/ritonavir); TECHNIVIE^™ (ombitasvir/paritaprevir/ritonavir); ZEPATIER^® (elbasvir/grazoprevir); or DAKLINZA^™ (daclatasvir).

VOSEVI is also indicated for chronic hepatitis C infection with genotype 1a or 3 and previous treatment with a regimen containing SOVALDI^® (sofosbuvir) without an NS5A inhibitor.

To learn more about Diplomat's hepatitis program, visit diplomat.is/areas-of-excellence/hepatitis.

VOSEVI is a fixed-dose, combination tablet administered once-daily with food for 12 weeks. It contains sofosbuvir and velpatasvir­, as well as the newly approved voxilaprevir.

"Diplomat is proud to expand its therapy offerings to patients who have been diagnosed with chronic hepatitis C," said Paul Urick, president of Diplomat. "Providing an opportunity to treat patients who have failed current treatment options, this combination tablet is a valuable addition to our product offering."

More than 2.7 million Americans have hepatitis C, according to the Centers for Disease Control and Prevention. Hepatitis C infection becomes chronic in approximately 75–85 percent of cases. Unlike many serious diseases, hepatitis C can be cured with treatment.

Hepatitis C causes liver inflammation. Some people with chronic hepatitis C infection develop cirrhosis, in which liver tissue is replaced by scar tissue, eventually preventing the liver from functioning properly.

VOSEVI is manufactured by Gilead Sciences, Inc. For full prescribing information, click here.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.

CONTACT:
Kali Lucas, Public Relations Specialist
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP
Executive Vice President of Operations
810.768.9863 | grice@diplomat.is

View original content with multimedia:http://www.prnewswire.com/news-releases/diplomat-now-dispensing-vosevi-to-treat-chronic-hepatitis-c-virus-300494212.html

SOURCE Diplomat Pharmacy, Inc.